Untitled case

I'll verify this case against public sources before writing.

Case Overview — 2:10-cv-00540 (E.D. Tex.), U.S. Patent No. 4,965,188

Verification status first, because it materially affects how the rest of this should be read. I was unable to confirm this docket in this session. Searches against Justia's E.D. Tex. docket archive, CourtListener/RECAP, and general web/PACER-adjacent sources returned no hit for "2:10-cv-00540" as a patent case, and no source tying U.S. Patent No. 4,965,188 to an Eastern District of Texas suit. The only metadata I can treat as authoritative is what you supplied: case number, court, and patent number. That metadata is internally anomalous in a way that should be flagged rather than papered over: the '188 patent is one of the foundational PCR (polymerase chain reaction) patents — "Process for amplifying, detecting, and/or cloning nucleic acid sequences," issued October 23, 1990, naming Kary Mullis, Henry Erlich, David Gelfand, Randall Saiki and Stephen Scharf, originally assigned to Cetus Corporation and later controlled by Hoffmann-La Roche. Its term expired in the mid-2000s (commonly cited as March 2005), so a 2010 infringement complaint asserting it would be unusual — though not impossible if the claims at issue involve past damages within the statutory look-back period, or if the case is a declaratory judgment, licensing, or contract dispute rather than a conventional infringement action. The other plausible explanation is a data error in the upstream litigation feed (Google Patents/Unified Patents litigation tables are aggregations and are known to contain number mapping errors); the patent number may be garbled or the docket may belong to another district. I am not asserting either explanation as fact — both are open and the docket needs to be pulled directly.

The patent, technically. U.S. 4,965,188 claims a process for amplifying a nucleic acid sequence: combining a template with primers, synthesizing extension products under polymerase conditions, denaturing the resulting duplexes, and repeating the cycle so the target sequence is amplified exponentially. In plain terms, it is a claim to the PCR thermal-cycling method itself, and it sits in the same family as U.S. 4,683,195 and 4,683,202. Historically this family was the subject of the Cetus–Roche transaction (Roche acquired PCR rights from Cetus in 1991) and of earlier enforcement, including Roche's litigation against Promega over PCR/Taq-related patents that produced a Federal Circuit decision in 2003. In a 2010 suit, the realistically interested plaintiff side would be Roche or an exclusive licensee/successor in the PCR estate, and the accused technology would be a nucleic-acid amplification instrument, reagent kit, or diagnostic assay practicing thermal cycling — but please treat the party identification and the accused-product description as unverified inference, not findings. I could not confirm the plaintiff, the defendant, or the accused product from any source, and I would not repeat a guessed party name in a filing or client memo.

Posture, venue, and why it would (or wouldn't) matter. The "2:" prefix indicates the Marshall Division, which in 2010 was the busiest patent venue in the country and the epicenter of the NPE/PAE assertion wave; if this is a genuine Marshall patent case from 2010, the venue significance is that it lands in the era of Judge T. John Ward's patent-heavy docket and the local-rule rocket docket that made E.D. Tex. the preferred forum for plaintiffs, before TC Heartland (2017) curtailed forum shopping. Because the patent would have been expired or near-expired, an IPR linkage is very unlikely — the PTAB did not exist in its current form until September 2012, and expired patents are poor IPR candidates — so this case is not notable for PTAB activity. Its real interest, if confirmed, would be as a data point in the tail of the PCR patent estate's enforcement history or as a litigation-feed artifact. To close the gaps, the next steps are: (1) pull the docket directly from PACER for E.D. Tex. 2:10-cv-00540; (2) cross-check CourtListener's RECAP entry and Bloomberg Law/RPX for the same number; (3) confirm the patent number against the USPTO Patent Center and assignment records to rule out a transposition error; and (4) if the docket is real and non-PCR, re-run the search without the patent number. I'd rather hand you four verified gaps than three invented paragraphs.

Bottom line up front: the docket could not be verified, and the metadata is probably wrong

I was unable to locate any public record of an Eastern District of Texas case numbered 2:10-cv-00540 involving U.S. Patent No. 4,965,188. Targeted searches of the open web (court-opinion databases, RECAP-derived indexing, SEC litigation disclosures, and patent-blog coverage) returned no hits for that docket number, and no hit pairing the '188 patent with a 2010 EDTX complaint. Because the case string in your metadata is itself flagged "Status: unverified," and because the timing problem described below is severe, I have to report that the chronological event list you asked for cannot be responsibly reconstructed from public sources. I am not going to invent docket entries, Markman dates, or counsel.

What I can do is (a) state the verified facts about the '188 patent that bear directly on whether such a case is even possible, (b) give the leading explanations for the metadata, and (c) tell you exactly which queries will resolve it.

---

Verified facts about the asserted patent that constrain the whole inquiry

U.S. Patent No. 4,965,188 — "Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme," inventors Mullis et al., issued 1990-10-23, originally assigned to Cetus Corporation and later owned by Roche Molecular Systems, Inc. / F. Hoffmann-La Roche Ltd as part of the "PCR Technology" portfolio (the '188 patent is the thermostable-polymerase (Taq) PCR patent, paired in every Roche license with the '195 and '202 patents).

Critically, the patent carried a terminal disclaimer and its term ended 2004-07-28:

"Patent Number: 4,965,188 … Date of Patent: * Oct. 23, 1990 … *Notice: The portion of the term of this patent subsequent to Jul. 28, 2004 has been disclaimed."
— contemporaneous 1996 licensing notice, http://iubioarchive.bio.net/bionet/mm/methods/1996-April/042872.html

Roche's standard PCR license language confirms the portfolio framing: "B1 4,683,195, B1 4,683,202 and 4,965,188 … hereinafter 'PCR Technology,'" with Roche Molecular Systems (Alameda, CA) and Applied Biosystems administering up-front-fee and running-royalty licenses (see the standard PCR license/notice text reproduced at, e.g., https://www.lawinsider.com/dictionary/pcr-technology). The '188 patent is also cited in BPAI ex parte prosecution decisions as of the late 1990s (https://law.onecle.com/board-of-patent-appeals/1999/fd952839003.html).

Three consequences that make a 2010 EDTX infringement suit on the '188 patent essentially incoherent:

1. The patent had been expired for roughly six years by the date of any 2010 filing. With a 2004-07-28 term end and the six-year damages lookback in 35 U.S.C. § 286, a complaint filed in 2010 could at most reach pre-expiration conduct ending in mid-2004 — i.e., a sliver of back damages and no injunctive relief.
2. No PTAB proceeding is possible. The '188 patent's effective filing date is in the mid-1980s, so PGR is categorically unavailable (post-AIA filing date requirement, 35 U.S.C. § 321). IPR did not exist until 2012-09-16, eight years after the patent expired; no IPR on the '188 patent appears in any public PTAB database I could reach, and none would be economically rational against an expired patent with no forward-looking royalty exposure. So the "parallel PTAB IPR effect on the litigation" bullet is, on the verified record, a null set.
3. The Roche PCR licensing program wound down after the core Cetus patents expired (the '188 patent in 2004, followed by the Taq polymerase patents), which is why the 2004–2005 period, not 2010, is the tail end of '188-driven enforcement.

---

Chronological framework, item by item, with verification status

Filing & initial pleadings — NOT VERIFIED. No complaint, answer, counterclaim, or corporate-disclosure filing for 2:10-cv-00540 (E.D. Tex.) could be located. I cannot identify plaintiff, defendant, accused product, or filing date.

Pre-trial motions (dismiss/transfer/stay/summary judgment) — NOT VERIFIED. No opinion, order, or docket entry surfaced.

Claim construction / Markman — NOT VERIFIED. No Markman order or hearing transcript for this docket number surfaced. Note that if a 2010 EDTX case had genuinely gone through Markman on the '188 patent, a claim-construction order would almost certainly be indexed somewhere; its total absence is itself evidence the case did not reach that stage (or does not exist as described).

Discovery milestones — NOT VERIFIED.

Trial, verdict, JMOL/new trial/fees — NOT VERIFIED. No verdict, judgment, or fee award found.

Final disposition/appeal — NOT VERIFIED. No Rule 41 dismissal order, no Federal Circuit appeal docket, no settlement announcement.

Parallel PTAB proceedings — NONE IDENTIFIED, and structurally implausible for the reasons in point 2 above. The '188 patent's contested validity history ran through the 1990s Article III and ex parte/reexamination channels (including the Cetus/Roche enforcement campaigns against Taq polymerase suppliers such as Promega), not through the AIA trial regime.

---

The most likely explanations for the metadata

Ranked by plausibility:

1. Data-mapping artifact in the Google Patents / Unified Patents litigation table. These tables frequently associate a patent family with docket numbers drawn from complaint-caption scraping; a case in the same family (e.g., a later-issued PCR/Taq-family patent, or a case in which the '188 patent was merely cited in a pleading, expert report, or IDS) can get attached to the '188 record. The "parties, filing date, and disposition could not be confirmed in the narrative" language in the existing summary is consistent with an entry that has a docket number but no substantive record.
2. A non-infringement dispute that references the patent — e.g., a license/royalty or indemnity action implicating the Roche "PCR Technology" definition, where the '188 patent appears contractually rather than as an asserted claim.
3. A complaint that nominally named the expired '188 patent alongside live family members and was promptly dismissed or amended to drop it — such a filing would generate almost no reported decisions.
4. A transposed or mistyped docket number/year. E.D. Tex. Marshall Division docket numbers in the 2:10-cv-5xx range are heavily populated by 2010 NPE filings (MobileMedia, Bandspeed, TQP, etc.), which raises the chance of a one-off digit collision in the source database.

I want to be plain: I could not confirm any of these. They are hypotheses, not findings.

What will actually resolve this — specific next steps

• PACER / CourtListener RECAP: query the E.D. Tex. docket 2:10-cv-00540 directly and pull the complaint PDF (the "Nature of Suit" code 830 and the patent list on the civil cover sheet will immediately confirm or kill the '188 attribution). CourtListener's RECAP docket endpoint accepts the exact docket string.
• Docket Navigator / Lex Machina / RPX Insight: search the '188 patent number as an asserted patent, filtering to 2010 and E.D. Tex.; these tools index asserted patents per complaint and would show whether the '188 was pled as a claim-bearing patent or merely mentioned.
• Roche Molecular Systems / Applied Biosystems enforcement history: confirm via Roche's 10-K/10-Q litigation disclosures and the Cetus/Roche Taq-polymerase case line (N.D. Cal.) whether any 2010 filing exists in the portfolio.
• PTAB P-TACTS / Unified Patents portal: search "4,965,188" as patent number across IPR/PGR/CBM — expect zero results, which I can state with reasonable confidence on the basis of the statutory and timing analysis above even absent a live database query.

Citation reliability note: the only sources I am able to ground here are (i) the 1990-10-23 issue date and 2004-07-28 terminal disclaimer (bio.net licensing notice) and (ii) the Roche "PCR Technology" portfolio definition including the '188 patent (reproduced license language). Everything in the requested chronological list is unsourced and unconfirmed, and should be treated as an open research item rather than a finding.

I'll research this docket and the '188 patent family.

I'll start by trying to locate the docket and any party/counsel records.

Defendant's counsel — 2:10-cv-00540 (E.D. Tex.)

Result: I cannot populate this section, and I will not populate it by inference. I did not identify a single attorney of record for any defendant, because I could not verify that this docket exists, could not verify any party name, and therefore have no "defendant" whose counsel I could look up. The table below is deliberately empty rather than guessed.

This is a hard stop, not a research gap I can paper over. Naming counsel is the one part of a case write-up where a plausible-sounding guess is worse than a blank: an attorney's appearance in a patent case is a discrete, checkable docket fact, and any name I supplied here would be fabricated. Consistent with the earlier sections (which already flagged the docket as unconfirmed and the '188 patent/2010-filing combination as anomalous), I am recording the absence of verification rather than filling it.

What I searched this session, and what came back

• "2:10-cv-00540" combined with Eastern District of Texas / patent — zero results.
• "2:10-cv-540" / "2:10-cv-00540" Marshall Division 2010 — no docket hit (search returned unrelated Texas state appellate material).
• 4,965,188 + Eastern District of Texas + 2010 — no litigation hit. Results returned unrelated E.D. Tex. matters (VirnetX, TQP, Personalized Media, Ho Keung Tse) and general E.D. Tex. patent-volume commentary; none mentions the '188 patent.
• "Patent No. 4,965,188" + complaint/defendants; 4,965,188 + Roche PCR + 2010 — returned only the Roche/Stanford line of cases (N.D. Cal. 3:05-cv-04158, Bd. of Trustees of Leland Stanford Junior Univ. v. Roche Molecular Systems, 563 U.S. 776 (2011)), the Roche–Promega Taq litigation, and PCR licensing/EEA material. No E.D. Tex. docket and no 2010 complaint asserting the '188 patent.
• A Unified Patents litigation-portal query for patent 4965188 and a CourtListener query for the docket number were cut off by my search-step limit before returning usable results — so those two avenues are incomplete, not negative.

What is confirmed vs. not

• Confirmed: The '188 patent ("Process for amplifying, detecting, and/or cloning nucleic acid sequences," Mullis/Erlich/Gelfand/Saiki/Scharf, Cetus → Roche) is real and is one of the three foundational PCR patents, licensed together with U.S. 4,683,202 and 4,683,195 (this is stated verbatim in Roche/Applied Biosystems PCR license notices).
• Confirmed: Roche-related PCR enforcement history runs through N.D. Cal. (Roche v. Promega; Stanford v. Roche) and the Federal Circuit — not through E.D. Tex.
• Not confirmed — do not rely on: that 2:10-cv-00540 exists; that it is a patent case; that it concerns the '188 patent; the identity of any plaintiff or defendant; whether any defendant appeared; whether any filing is sealed; whether the case was dismissed on filing or transferred.

Because defendant's counsel is downstream of "who is the defendant," and the defendant is unverified, there is no defensible way to reach the counsel question yet. In particular I have no basis to say counsel "hasn't appeared yet" or that filings are "sealed" — either statement would itself be an invented docket fact.

To close this in one pass (30–60 minutes of docket work)

1. PACER directly: E.D. Tex. CM/ECF, Docket Report for 2:10-cv-00540. Look at (a) the case title/short style, (b) the "Attorneys" pane or the "Lead Attorney" designation in the docket report header, and (c) the complaint's signature block. If the case number returns "case not found," that itself is the finding — the litigation-feed entry is bad.
2. Sanity-check the number: E.D. Tex. numbering in 2010 was division-prefixed (2: = Marshall). If the real case is Tyler (6:10-cv-…) or Beaumont (1:10-cv-…), re-run by party name, not number.
3. CourtListener RECAP and Bloomberg Law / RPX / Docket Navigator for the same number — these will often surface the complaint PDF and the appearance entries even when PACER is down.
4. Confirm the patent number against USPTO Patent Center and the assignment reel (Cetus → Roche) before treating '188 as the patent-in-suit. Given the term expiry (commonly cited as March 2005), the likeliest benign explanations remain (i) a number-transposition error in the Google Patents/Unified Patents aggregation, or (ii) a non-infringement posture (declaratory judgment, license/contract, or past-damages look-back) rather than a conventional 2010 infringement count. Both remain hypotheses.
5. Once the docket is in hand, counsel is mechanical: the "Attorneys" pane plus every NOTICE of Appearance / pro hac vice motion. Expect the E.D. Tex. 2010 pattern — out-of-district lead counsel admitted pro hac vice paired with local counsel admitted to the Eastern District bar — so the answer will likely be a pair per defendant, plus any in-house counsel listed on the corporate disclosure statement (Fed. R. Civ. P. 7.1).

Handoff note: if you can pull even a screenshot of the PACER docket header (case style + attorneys pane), I can complete this section — roles, firms, offices, and patent-litigation backgrounds for each named attorney — with proper sourcing in a single follow-up.